C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment

In a previous analysis of patients with limited vs more advanced lung function impairment, increases in University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores were more pronounced in patients with GAP stage II/III vs GAP stage I and in patients with baseline FVC <...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser:	Glassberg, M K, Wijsenbeek, M, Gilberg, F, Petzinger, U, Kirchgassler, K-U, Albera, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Pulmonary fibrosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title	American journal of respiratory and critical care medicine
container_volume	195
creator	Glassberg, M K Wijsenbeek, M Gilberg, F Petzinger, U Kirchgassler, K-U Albera, C
description	In a previous analysis of patients with limited vs more advanced lung function impairment, increases in University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores were more pronounced in patients with GAP stage II/III vs GAP stage I and in patients with baseline FVC < 80% vs FVC > 80% (Albera et al., EurRespir J., 2016). Evaluation of categorical change for patients with GAP stage II/III demonstrated that pirfenidone reduced the proportion of patients with UCSD-SOBQ score increases of > 15 points (45.6% vs 38.4%; P = 0.0449) and > 20 points (37.7% vs 28.6%; P = 0.0089) at 12 months compared with placebo; increases of > 5 or > 10 points were similar between treatment groups.
format	Article
fullrecord	<record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1926861724</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926861724</sourcerecordid><originalsourceid>FETCH-proquest_journals_19268617243</originalsourceid><addsrcrecordid>eNqNjMtKw0AYhYMoWC_vcMCNLgJJk97c9ZLYAZuGJkV3ZZr8sVPSmXRmsuhD-k4G9AFcHM6B8_FdOT1_EAzccDLyrrvtjQI3DCeft86dMUfP8_tj3-s53_NgjG2yiDZZPk0WLHlDvow20zTa5myegSVgafyKqKqosFhXSIWuSIpSScJaYqaJ20NNxsgumBqsiJtWU4nZBfmBsC1M6WZqf0ZWKE1gEim3gqQ1-BD2AFYK1XQSUSBt65OSXF8Qi71WRhg8i6Z6-QVXqiTNLeG9lV-IW1lYoSTYqeFCnzrhg3NT8drQ41_fO09xlM-XbqPVuSVjd0fVatldO3_SH46H_qgfBv-jfgAZ-mkw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926861724</pqid></control><display><type>article</type><title>C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><source>American Thoracic Society (ATS) Journals Online</source><source>Alma/SFX Local Collection</source><creator>Glassberg, M K ; Wijsenbeek, M ; Gilberg, F ; Petzinger, U ; Kirchgassler, K-U ; Albera, C</creator><creatorcontrib>Glassberg, M K ; Wijsenbeek, M ; Gilberg, F ; Petzinger, U ; Kirchgassler, K-U ; Albera, C</creatorcontrib><description>In a previous analysis of patients with limited vs more advanced lung function impairment, increases in University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores were more pronounced in patients with GAP stage II/III vs GAP stage I and in patients with baseline FVC < 80% vs FVC > 80% (Albera et al., EurRespir J., 2016). Evaluation of categorical change for patients with GAP stage II/III demonstrated that pirfenidone reduced the proportion of patients with UCSD-SOBQ score increases of > 15 points (45.6% vs 38.4%; P = 0.0449) and > 20 points (37.7% vs 28.6%; P = 0.0089) at 12 months compared with placebo; increases of > 5 or > 10 points were similar between treatment groups.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><language>eng</language><publisher>New York: American Thoracic Society</publisher><subject>Pulmonary fibrosis</subject><ispartof>American journal of respiratory and critical care medicine, 2017-01, Vol.195</ispartof><rights>Copyright American Thoracic Society 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids></links><search><creatorcontrib>Glassberg, M K</creatorcontrib><creatorcontrib>Wijsenbeek, M</creatorcontrib><creatorcontrib>Gilberg, F</creatorcontrib><creatorcontrib>Petzinger, U</creatorcontrib><creatorcontrib>Kirchgassler, K-U</creatorcontrib><creatorcontrib>Albera, C</creatorcontrib><title>C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment</title><title>American journal of respiratory and critical care medicine</title><description>In a previous analysis of patients with limited vs more advanced lung function impairment, increases in University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores were more pronounced in patients with GAP stage II/III vs GAP stage I and in patients with baseline FVC < 80% vs FVC > 80% (Albera et al., EurRespir J., 2016). Evaluation of categorical change for patients with GAP stage II/III demonstrated that pirfenidone reduced the proportion of patients with UCSD-SOBQ score increases of > 15 points (45.6% vs 38.4%; P = 0.0449) and > 20 points (37.7% vs 28.6%; P = 0.0089) at 12 months compared with placebo; increases of > 5 or > 10 points were similar between treatment groups.</description><subject>Pulmonary fibrosis</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNjMtKw0AYhYMoWC_vcMCNLgJJk97c9ZLYAZuGJkV3ZZr8sVPSmXRmsuhD-k4G9AFcHM6B8_FdOT1_EAzccDLyrrvtjQI3DCeft86dMUfP8_tj3-s53_NgjG2yiDZZPk0WLHlDvow20zTa5myegSVgafyKqKqosFhXSIWuSIpSScJaYqaJ20NNxsgumBqsiJtWU4nZBfmBsC1M6WZqf0ZWKE1gEim3gqQ1-BD2AFYK1XQSUSBt65OSXF8Qi71WRhg8i6Z6-QVXqiTNLeG9lV-IW1lYoSTYqeFCnzrhg3NT8drQ41_fO09xlM-XbqPVuSVjd0fVatldO3_SH46H_qgfBv-jfgAZ-mkw</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Glassberg, M K</creator><creator>Wijsenbeek, M</creator><creator>Gilberg, F</creator><creator>Petzinger, U</creator><creator>Kirchgassler, K-U</creator><creator>Albera, C</creator><general>American Thoracic Society</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment</title><author>Glassberg, M K ; Wijsenbeek, M ; Gilberg, F ; Petzinger, U ; Kirchgassler, K-U ; Albera, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19268617243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Pulmonary fibrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glassberg, M K</creatorcontrib><creatorcontrib>Wijsenbeek, M</creatorcontrib><creatorcontrib>Gilberg, F</creatorcontrib><creatorcontrib>Petzinger, U</creatorcontrib><creatorcontrib>Kirchgassler, K-U</creatorcontrib><creatorcontrib>Albera, C</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glassberg, M K</au><au>Wijsenbeek, M</au><au>Gilberg, F</au><au>Petzinger, U</au><au>Kirchgassler, K-U</au><au>Albera, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>195</volume><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>In a previous analysis of patients with limited vs more advanced lung function impairment, increases in University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores were more pronounced in patients with GAP stage II/III vs GAP stage I and in patients with baseline FVC < 80% vs FVC > 80% (Albera et al., EurRespir J., 2016). Evaluation of categorical change for patients with GAP stage II/III demonstrated that pirfenidone reduced the proportion of patients with UCSD-SOBQ score increases of > 15 points (45.6% vs 38.4%; P = 0.0449) and > 20 points (37.7% vs 28.6%; P = 0.0089) at 12 months compared with placebo; increases of > 5 or > 10 points were similar between treatment groups.</abstract><cop>New York</cop><pub>American Thoracic Society</pub></addata></record>
fulltext	fulltext
identifier	ISSN: 1073-449X
ispartof	American journal of respiratory and critical care medicine, 2017-01, Vol.195
issn	1073-449X 1535-4970
language	eng
recordid	cdi_proquest_journals_1926861724
source	Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload; American Thoracic Society (ATS) Journals Online; Alma/SFX Local Collection
subjects	Pulmonary fibrosis
title	C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A42%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C38%20UNDERSTANDING%20THERAPEUTICS%20IN%20IPF:%20Effect%20Of%20Pirfenidone%20On%20Breathlessness%20As%20Measured%20By%20The%20Ucsd-Sobq%20Score%20In%20Patients%20With%20Idiopathic%20Pulmonary%20Fibrosis%20(ipf)%20With%20Moderate%20Lung%20Function%20Impairment&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Glassberg,%20M%20K&rft.date=2017-01-01&rft.volume=195&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/&rft_dat=%3Cproquest%3E1926861724%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926861724&rft_id=info:pmid/&rfr_iscdi=true